Objective To investigate clinical characteristics and prognosis of the end-stage kidney disease (ESKD) patients undergoing hemodialysis and complicated with cardiorenal anemia syndrome (CRAS). Methods This was a retrospective cohort study. We recruited the baseline demographic and clinical data of the ESKD patients undergoing hemodialysis patients and complicated with CRAS admitted to the Hospital from August 2012 to August 2021. According to the left ventricular ejection fraction (LVEF) at baseline, they were divided into LVEF ≤40% group, LVEF ≥41% ～≤49% group, and LVEF ≥50% group. The baseline data were compared among the three groups. They were followed up until July 31, 2022 or death. Cox regression model was used to analyze the risk factors for all-cause mortality of the patients. The relationship between LVEF and all-cause mortality risk was analyzed by generalized additive model smoothing curve fitting and multivariate Cox regression model. Results A total of 386 ESKD hemodialysis patients with CRAS were included in this study, with a median age of 58 (46，70) years old and 252 males (65.28%). During the follow-up interval [median 32(17，52) months], 164 patients (42.49%) died. Multivariate Cox regression showed that age (HR=1.049, 95% CI: 1.033～1.064, P＜0.001), dialysis age (HR=1.007, 95% CI: 1.002～1.011, P=0.004), cerebral infarction (HR=1.748, 95% CI:1.087～2.812, P=0.021), New York Heart Association (NYHA) heart functional grade (HR=1.455, 95% CI: 1.045～2.024, P=0.026), and LVEF (HR=0.695, 95% CI: 0.579～0.836, P=0.001) were the independent predictors for all-cause mortality in ESKD hemodialysis patients with CRAS. Generalized additive model smoothing curve fitting model showed that LVEF level was linearly correlated with the mortality risk trend of the patients (log-likelihood ratio test, P=0.043). Conclusions LVEF is an independent protective factor for mortality risk in ESKD hemodialysis patients with CRAS. Early diagnosis and management of lower LVEF is therefore essential to prognosis of these patients.
ZHU Meng-Yue
,
LU Chun-Lei
,
LIU Min
,
HE Da-Feng
,
BI Guang-Yu
,
RONG -wang
. Clinical characteristics and prognosis of the hemodialysis patients with end-stage kidney disease and cardiorenal anemia syndrome[J]. Chinese Journal of Blood Purification, 2025
, 24(02)
: 132
-136
.
DOI: 10.3969/j.issn.1671-4091.2025.02.007
[1] Al-Jarallah M, Rajan R, Al-Zakwani I, et al. Incidence and impact of cardiorenal anaemia syndrome on all-cause mortality in acute heart failure patients stratified by left ventricular ejection fraction in the Middle East[J]. ESC Heart Fail. 2019. 6(1): 103-110.
[2] Kim CJ, Choi IJ, Park HJ, et al. Impact of Cardiorenal Anemia Syndrome on Short- and Long-Term Clinical Outcomes in Patients Hospitalized with Heart Failure[J]. Cardiorenal Med. 2016. 6(4): 269-78.
[3] Pallangyo P, Fredrick F, Bhalia S, et al. Cardiorenal Anemia Syndrome and Survival among Heart Failure Patients in Tanzania: A Prospective Cohort Study[J]. BMC Cardiovasc Disord. 2017. 17(1): 59.
[4] Lu KJ, Kearney LG, Hare DL, et al. Cardiorenal anemia syndrome as a prognosticator for death in heart failure[J]. Am J Cardiol. 2013. 111(8): 1187-91.
[5] Scrutinio D, Passantino A, Santoro D, Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival[J]. Eur J Heart Fail. 2011. 13(1): 61-7.
[6] McCullough PA. Anemia of cardiorenal syndrome[J]. Kidney Int Suppl (2011). 2021. 11(1): 35-45.
[7] McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J. 2023. 44(37): 3627-3639.
[8] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med. 2011 Sep 20;155(6):408][J]. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
[9] World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO, 2011.
[10] McCullough PA. Anemia of cardiorenal syndrome[J]. Kidney Int Suppl. 2021. 11(1): 35-45.
[11] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation. 2022. 145(18): e895-e1032.
[12] 崔晓通, 王鹏, 金雪娟等. 中国不同射血分数亚型心力衰竭住院患者临床特征分析[J]. Sci Immunol. 2023. 30(5): 759-762.
[13] Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study[J]. Am J Cardiol. 2000. 86(10): 1090-6.
[14] Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort[J]. J Am Coll Cardiol. 1999. 33(7): 1948-55.
[15] Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study[J]. Ann Intern Med. 2002. 137(8): 631-9.
[16] Kondo T, Dewan P, Anand IS, et al. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification[J]. Circulation. 2023. 148(9): 732-749.
[17] Kupari M, Lindroos M, Iivanainen AM, Heikkil? J, Tilvis R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study[J]. J Intern Med. 1997. 241(5): 387-94.
[18] Huynh K. Heart failure: Improvement of LVEF in patients with HF is linked to better prognosis[J]. Nat Rev Cardiol. 2016. 13(9): 505.
